First FDA-Approved FSGS Drug: Sparsentan (Filspari) Overview
First FDA-approved FSGS drug: Sparsentan (Filspari) approved April 2026. ETAR/AT1R dual antagonism, DUPLEX trial results, Apecotrep & Inaxaplin pipeline.
Breaking: FSGS Gets Its First-Ever FDA-Approved Drug
On April 13, 2026, the FDA granted full approval to Sparsentan (Filspari, Travere Therapeutics) for proteinuria reduction in adult and pediatric patients (aged ≥8 years) with focal segmental glomerulosclerosis (FSGS) who do not have nephrotic syndrome — marking the first FDA-approved disease-modifying therapy for FSGS in history[1].
For decades, FSGS management was limited to supportive care: RAS inhibition for blood pressure and proteinuria control, with immunosuppression reserved for selected patients despite modest efficacy. Today, that changes. Sparsentan's approval shifts the competitive landscape from "first mover" to "beating the approved benchmark" — and it has immediate implications for researchers designing FSGS preclinical and clinical programs.
1. Approval at a Glance
| Item | Detail |
|---|---|
| Drug | Sparsentan (brand: Filspari) |
| Developer | Travere Therapeutics |
| Indication | FSGS (without nephrotic syndrome): proteinuria reduction in adults and children ≥8 years |
| Approval Date | April 13, 2026 (FDA full approval) |
| Evidence Base | DUPLEX Phase 3 |
| Mechanism | Dual endothelin A receptor (ETAR) + angiotensin II type 1 receptor (AT1R) antagonism |
| Route | Oral, once daily |
| Prior Approval | IgA nephropathy (FDA full approval 2024, PROTECT trial) |
Sparsentan is now the only drug with formal FDA approval for two distinct glomerular diseases[6]. This dual-indication positioning makes Travere uniquely resilient in the nephrology space.
For researchers tracking fibrosis & inflammation R&D
FDA approval alerts, trial readouts, preclinical model selection, and assay optimization — curated signal for bench-to-pipeline readers. 2 emails/month max.
2. FSGS: Why Drug Development Has Been So Hard
FSGS is a rare primary glomerular disease characterized by localized scarring of kidney glomeruli. Podocyte injury is the central pathological event.
- Prevalence: ~40,000 patients in the US; ~5,400 new cases/year (orphan disease designation)
- Prognosis: ~50% progress to end-stage renal disease (ESKD) within 10 years without effective treatment
- Standard of care: RAS inhibitors (ACEi/ARB) for proteinuria and blood pressure management only
- Disease heterogeneity: Primary, genetic, secondary, and idiopathic subtypes with different etiologies make a single-target approach insufficient for all patients
Podocytes highly express both ETAR and AT1R. Activation of these two receptors drives glomerular permeability → proteinuria → progressive sclerosis — the mechanism Sparsentan's dual antagonism directly addresses.
3. Mechanism of Action: Why Dual ETAR/AT1R Antagonism?
Sparsentan is a single molecule that simultaneously blocks ETAR and AT1R — an approach designed to intercept two parallel drivers of podocyte injury. According to FDA prescribing information, Sparsentan binds with high affinity to both receptors (ETAR Ki = 12.8 nM, AT1R Ki = 0.36 nM) and exhibits greater than 500-fold selectivity over the closely related ETBR and AT2R receptors[7]. This ETBR-sparing selectivity is a key design feature aimed at avoiding the fluid-retention liability associated with non-selective endothelin receptor antagonists.
ETAR pathway: Endothelin-1 (ET-1) acting via ETAR triggers podocyte cytoskeletal disruption, slit diaphragm damage, and glomerular contraction. ET-1 also activates TGF-β and RhoA/ROCK signaling, accelerating glomerulosclerosis. ERA monotherapy has shown proteinuria benefit historically, but systemic ETBR blockade-related fluid retention remained a limiting factor. Sparsentan is ETAR-selective, minimizing this risk.
AT1R pathway: Angiotensin II acting via AT1R drives efferent arteriolar constriction, elevated intraglomerular pressure, TGF-β production, and renal fibrosis. ARBs partially address this pathway but leave ET-1-mediated injury intact.
Dual blockade rationale: By blocking both receptors simultaneously, Sparsentan surpasses the ceiling of ARB monotherapy. The superiority over irbesartan (AT1R-only) demonstrated in DUPLEX provides clinical proof of this additive mechanism.
4. Clinical Evidence: DUPLEX Phase 3 Trial
DUPLEX (N Engl J Med. 2024) was a 371-patient randomized, double-blind, active-controlled trial comparing Sparsentan head-to-head against irbesartan over 108 weeks (~2 years) — described as the largest interventional FSGS study to date[2].
| Endpoint | Sparsentan | Irbesartan |
|---|---|---|
| Trial size | 371 patients (Phase 3) | — |
| Primary EP: eGFR total slope (Day 1 → Week 108) | Between-group diff 0.3 mL/min/1.73m²/yr (95% CI −1.7 to 2.4; p=0.75, NOT significant) | — |
| Secondary: Proteinuria reduction (Week 108, UPCR LS geometric mean) | 50.0% reduction (95% CI 40.8–57.7) | 32.3% reduction (95% CI 20.2–42.6) |
| Partial remission of proteinuria (108 wk) | 37.5% | 22.6% |
| Complete remission of proteinuria (108 wk) | 18.5% | 7.5% |
Notably, the prespecified primary endpoint — eGFR total slope at Week 108 — did NOT reach statistical significance (p=0.75)[2]. Full approval was nonetheless granted based on the robust secondary proteinuria benefit (50.0% vs 32.3% reduction) and higher remission rates (partial: 37.5% vs 22.6%; complete: 18.5% vs 7.5%)[2]. Travere's press release reports a 46% vs 30% proteinuria reduction at Week 108[1], differing from the NEJM LS geometric mean figures due to distinct analytical methods.
Important limitation: The approval is restricted to FSGS without nephrotic syndrome. Patients with heavy proteinuria at nephrotic-range levels are not covered by the current label. The pediatric indication (≥8 years) is a meaningful addition, expanding the potential patient population.
5. Competing Pipeline: The Post-Filspari Race
Sparsentan's approval does not close the FSGS drug development chapter — it opens the "beat the approved drug" era. Here are the key pipeline candidates.
Apecotrep (BI 764198) | Boehringer Ingelheim
- MOA: TRPC6 (transient receptor potential cation channel C6) inhibition — first-in-class
- Status: Phase 3 recruiting (Phase 2 data published in Lancet 2026: ~40% proteinuria reduction at 12 weeks in the 20 mg group)[5]
- Differentiation: Podocyte-specific mechanism, no immunosuppression
- Scientific rationale: TRPC6 is essential for podocyte calcium homeostasis. Gain-of-function (GOF) mutations in TRPC6 cause familial FSGS. Blocking TRPC6 directly addresses a validated disease driver.
TRPC6 gain-of-function mutations identified in familial FSGS provide genetic validation for this target class. Podocyte-specific TRPC6 transgenic mouse models are widely used to evaluate TRPC6-pathway-targeted compounds.
Inaxaplin (VX-147) | Vertex Pharmaceuticals
- MOA: Oral small-molecule APOL1 inhibitor (first-in-class)
- Status: Adaptive Phase 2/3 AMPLITUDE trial (NCT05312879) has advanced into the Phase 3 portion (45 mg once daily vs placebo, on top of standard of care)
- Patient selection: Enrolls patients with APOL1-mediated kidney disease (AMKD) who carry APOL1 high-risk (G1/G2) alleles — a precision medicine approach. FSGS is a major subpopulation, and the FDA has granted Breakthrough Therapy Designation specifically for APOL1-mediated FSGS
- Clinical relevance: A substantial proportion of primary FSGS in patients of African ancestry is attributable to APOL1 variants. If approved, Inaxaplin would serve a genotype-defined population that partially overlaps with Filspari's label
Atacicept | Vera Therapeutics
- MOA: Dual BAFF/APRIL inhibition (targets B cell and plasma cell-driven autoimmunity)
- Status: IgA nephropathy BLA under Priority Review (PDUFA: July 7, 2026), accelerated approval filing based on ORIGIN 3 Phase 3 interim analysis
- FSGS relevance: Being evaluated in the PIONEER trial in patients with anti-nephrin antibody-positive FSGS and minimal change disease (MCD)
6. Preclinical Models for FSGS Drug Evaluation
For researchers developing the next generation of FSGS therapeutics, model selection determines translational relevance.
Adriamycin (ADR)-induced nephropathy is the established standard model for primary FSGS preclinical evaluation, with both Sprague Dawley rat and BALB/c mouse variants in use. Sparsentan's preclinical efficacy was evaluated in the Sprague Dawley rat ADR model, demonstrating glomerular basement membrane (GBM) and glycocalyx protection, proteinuria attenuation, and reduced glomerular injury[3]. The model supports composite endpoints mirroring clinical readouts: ACR, NGAL, histological scoring (PAS, Sirius Red), and podocyte quantification.
Podocyte-specific TRPC6 transgenic mouse models (Pod-TRPC6-Tg) enable in vivo assessment of glomerular hemodynamics and podocyte function under TRPC6 overexpression. Sparsentan has also been evaluated in this model, demonstrating significant afferent and efferent arteriolar dilation and protective tissue remodeling superior to losartan control[4]. Together, the chemical-induction (ADR) and genetic (TRPC6-Tg) models provide complementary perspectives for MOA-specific FSGS drug evaluation.
Model choice should match the compound's MOA: dual receptor antagonists (ETAR/AT1R) → ADR nephropathy; TRPC6 inhibitors → TRPC6 GOF transgenic models; APOL1-targeted agents → APOL1 risk allele knock-in models. See our renal fibrosis preclinical model comparison for a systematic framework.
7. Key Takeaways for Researchers
-
The benchmark has changed: Future FSGS clinical trials will need to demonstrate superiority or non-inferiority against Filspari — not just irbesartan. Preclinical programs should begin designing head-to-head comparisons accordingly.
-
Apecotrep Phase 3 is the next major catalyst: A TRPC6 inhibitor with a mechanistically distinct approach now in Phase 3 represents the most imminent competitive challenge to Filspari's position.
-
Precision medicine is converging on FSGS: Inaxaplin's APOL1-stratified approach, if successful, will demonstrate that biomarker-driven patient selection is viable in FSGS — reshaping how future trials are designed.
-
Pediatric indication opens new questions: Filspari's approval for patients ≥8 years raises the question of age-appropriate preclinical evaluation. Juvenile or young-adult model characterization may become increasingly relevant for FSGS program design.
Related Preclinical Models
See our Renal Fibrosis Models — UUO, adriamycin & folic acid models for FSGS translation.
References
1. Travere Therapeutics. Travere Therapeutics Announces Full FDA Approval of FILSPARI (sparsentan), the First and Only Approved Medicine for FSGS. Press release, 2026-04-13. Travere IR
2. Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis (DUPLEX Phase 3). N Engl J Med. 2024. DOI: 10.1056/NEJMoa2308550 / ClinicalTrials.gov: NCT03493685 (DUPLEX), NCT01613118 (DUET Phase 2)
3. Bedard P, Jenkinson C, Komers R. Sparsentan Protects the Glomerular Basement Membrane and Glycocalyx, and Attenuates Proteinuria in a Rat Model of Focal Segmental Glomerulosclerosis (FSGS) [MO255]. Nephrol Dial Transplant. 2022;37(Suppl 3):gfac067.054. ERA-EDTA Congress 2022. Abstract
4. Gyarmati G, et al. Sparsentan Improves Glomerular Blood Flow and Augments Protective Tissue Remodeling in Mouse Models of Focal Segmental Glomerulosclerosis (FSGS). Nephrol Dial Transplant. 2021;36(Suppl 1):gfab138.002. ERA-EDTA Congress 2021. Abstract
5. Apecotrep (BI 764198) Phase 2. Lancet. 2026. Article
6. Travere Therapeutics. Sparsentan pipeline page. travere.com
7. FILSPARI® (sparsentan) tablets, for oral use. FDA Prescribing Information (Reference ID: 5649655, Revised 8/2025). FDA accessdata